Status:
COMPLETED
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
Lead Sponsor:
AstraZeneca
Conditions:
Anxious Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will determine if a highly selective enkephalinergic receptor modulator is effective in the treatment of anxious major depressive disorder.
Eligibility Criteria
Inclusion
- Provision of informed consent prior to any study specific procedures
- Diagnosis of major depressive disorder without psychotic features (MDD)
Exclusion
- A history of substance or alcohol abuse within the past 6 months or dependence within 1 year of enrollment as defined by DSM-IV criteria.
- Women that are pregnant or lactating
- History of pancreatitis
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00759395
Start Date
January 1 2009
End Date
October 1 2011
Last Update
November 8 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Baltimore, Maryland, United States